Risks and benefits of phase 1 oncology trials, revisited

被引：65
|
作者：
Kurzrock, R
Benjamin, RS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Phase 1 Program, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 352卷 / 09期
关键词：
D O I：
10.1056/NEJMe058007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：930 / 932
页数：3
相关论文
共 50 条
  • [41] Therapeutic intent in phase 1 oncology trials - A justifiable objective
    Markman, Maurie
    ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (14) : 1446 - 1448
  • [42] Participants in Phase 1 Oncology Research Trials Are Vulnerable In reply
    Grady, Christine
    Seidenfeld, Justine
    Horstmann, Elizabeth
    Emanuel, Ezekiel J.
    ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (20) : 2288 - 2288
  • [43] Phase 1 trials in oncology in India: The clear case for innovation
    Sharma, Sunil
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2009, 5 (02) : 69 - 70
  • [44] Physician and Nurse Beliefs of Phase 1 Trials in Pediatric Oncology
    Barnes, Margaux J.
    Pressey, Joseph
    Adams, Julia
    Hensler, Molly A.
    Madan-Swain, Avi
    CANCER NURSING, 2014, 37 (05) : E48 - E52
  • [45] Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).
    Gan, H. K.
    You, B.
    Pond, G. R.
    Chen, E. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Decision theory and the evaluation of risks and benefits of clinical trials
    Bernabe, Rosemarie D. C.
    van Thiel, Ghislaine J. M. W.
    Raaijmakers, Jan A. M.
    van Delden, Johannes J. M.
    DRUG DISCOVERY TODAY, 2012, 17 (23-24) : 1263 - 1269
  • [47] Sham trials: benefits and risks for cardiovascular research and patients
    Fudim, Marat
    Ali-Ahmed, Fatima
    Patel, Manesh R.
    Sobotka, Paul A.
    LANCET, 2019, 393 (10186): : 2104 - 2106
  • [48] Commercializing clinical trials - Risks and benefits of the CRO boom
    Shuchman, Miriam
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (14): : 1365 - 1368
  • [49] Weighing the benefits and risks in clinical trials and practice - Introduction
    McCaskill-Stevens, W
    SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS), 2001, 949 : 279 - 279
  • [50] On risks and benefits of iron supplementation recommendations for iron intake revisited
    Schuemann, Klaus
    Ettle, Thomas
    Szegner, Bernadett
    Elsenhans, Bernd
    Solomons, Noel W.
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2007, 21 (03) : 147 - 168
12345